Papers/PMID:41374029
Effects of L-Citrulline Supplementation on Endothelial Function, Arterial Stiffness, and Blood Glucose Level in the Fasted and Acute Hyperglycemic States in Middle-Aged and Older Adults with Type 2 Diabetes.
Nutrients2025The record
2 findings drawn from this paper, on 1 compound across 2 endpoints, 1 of them null.
What it reported
How to read these marksWhat moved
1 finding
L-citrulline — increases flow-mediated dilation
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.Findingreplicated ×1“FMD improved in the fasted state after CIT supplementation compared to placebo (CIT: Δ1.3 ± 0.2% vs. Placebo: Δ−0.5 ± 0.1%, p < 0.01) A).”
Quoted verbatim from Effects of L-Citrulline Supplementation on Endothelial Function, Arterial Stiffness, and Blood Glucose Level in the Fasted and Acute Hyperglycemic States in Middle-Aged and Older Adults with Type 2 Diabetes.. - Study
- crossover
- Participants
- 16
- Duration
- 4 weeks
- Dose
- 6 g/day L-citrulline as 750 mg capsules, four in the morning and four in the evening, for 4 weeks
- Population
- Middle-aged and older adults with type 2 diabetes, mean age 62 years, treated with oral hypoglycaemic drugs and/or insulin, none doing structured exercise; measured in the fasted state.
What did not
1 finding
L-citrulline — no detected effect on HOMA-IR
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull result“Importantly, although we did not observe statistical significance in HOMA-IR, there was a decreasing trend in CIT and an increasing trend in placebo after 4 weeks.”
Quoted verbatim from Effects of L-Citrulline Supplementation on Endothelial Function, Arterial Stiffness, and Blood Glucose Level in the Fasted and Acute Hyperglycemic States in Middle-Aged and Older Adults with Type 2 Diabetes.. - Study
- crossover
- Participants
- 16
- Duration
- 4 weeks
- Dose
- 6 g/day L-citrulline as 750 mg capsules, four in the morning and four in the evening, for 4 weeks
- Population
- Middle-aged and older adults with type 2 diabetes, mean age 62 years, treated with oral hypoglycaemic drugs and/or insulin, none doing structured exercise.